Nuvectis Pharma, Inc. Stock Price, News & Analysis

Nuvectis Pharma reported encouraging interim data from its Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer patients. The study evaluated three dosing regimens in twelve patients, with one showing unconfirmed partial response and six achieving stable disease with tumor shrinkage. The new intermittent dosing schedule (50 mg/day, 5 days on/2 days off) successfully minimized thrombocytopenia concerns. The company is now enrolling patients for a higher dose intensity cohort at 75 mg/day on an intermittent schedule, with additional clinical data expected in Q2 2025.

Nuvectis Pharma reported Q3 2024 financial results and business updates. Cash position was $17.2M as of September 30, 2024, down from $19.1M in December 2023. Net loss decreased to $4.2M from $5.9M year-over-year. R&D expenses reduced to $2.8M from $4.5M, while G&A expenses decreased to $1.5M from $1.7M. The company expects clinical data update from NXP800 Phase 1b study this month, with the drug receiving Orphan Drug Designation for ARID1a-deficient cancers. NXP900 Phase 1a study completed 4 escalation cohorts with no dose-limiting toxicities.

Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.

The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.

Nuvectis Pharma (NASDAQ: NVCT) has announced two upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain (October 23-25, 2024).

The first presentation by Asier Unciti-Broceta from the University of Edinburgh will showcase NXP900's synergy with ALK inhibitors in ALK resistant cell lines. This poster session is scheduled for October 24th, 2024.

The second presentation by Ben King, also from the University of Edinburgh, will focus on using a multi-omics approach to identify biomarkers responding to NXP900. This poster session will take place on October 25th, 2024.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in innovative precision medicines for oncology, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is scheduled for October 9, 2024, in New York, NY.

Nuvectis management will take part in a panel discussion focused on 'Innovative Therapies for Solid Tumors'. This panel is set to begin at 12:30 pm ET on the day of the conference.

The company's involvement in this prestigious healthcare conference underscores its commitment to advancing treatments for serious conditions with unmet medical needs in oncology, particularly in the realm of solid tumors.

Nuvectis Pharma's NXP900 is emerging as a promising candidate in the fight against Non-Small Cell Lung Cancer (NSCLC), particularly for patients resistant to EGFR and ALK targeted therapies. Like Summit Therapeutics' Ivonescimab, which recently outperformed Merck's Keytruda in a Phase 3 trial, NXP900 targets treatment resistance but through a different mechanism.

NXP900 inhibits SRC/YES1 kinases, key drivers of cancer survival. Preclinical studies show its potential to reverse resistance to existing therapies and enhance their effectiveness when used in combination. While still in early clinical development, NXP900's targeted approach and potential applications beyond NSCLC make it a noteworthy contender in the evolving landscape of cancer treatment.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Chairman and CEO, Ron Bentsur, will be presenting at the event on September 9, 2024, at 12:00 PM ET.

Nuvectis focuses on developing innovative treatments for serious conditions with unmet medical needs in oncology. This presentation at a prominent investment conference provides an opportunity for the company to showcase its progress and potential to investors and industry professionals. Interested parties can access the presentation through a provided link, offering insight into Nuvectis' current projects and future prospects in the oncology field.

Nuvectis Pharma (NASDAQ: NVCT) has announced that its drug NXP800 has received Orphan Drug Designation from the FDA for treating ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. This designation is significant as ovarian cancer typically exceeds the 200,000 patient threshold for Orphan Drug eligibility. The company views this as validation for NXP800's mechanism of action and target patient population in their ongoing Phase 1b clinical trial for platinum-resistant, ARID1a-mutated ovarian cancer. Nuvectis plans to provide a data update from this study in fall 2024.

Nuvectis Pharma (NASDAQ: NVCT) reported its Q2 2024 financial results and business highlights. The company continues to advance clinical trials for NXP800 and NXP900. The Phase 1b trial for NXP800 in platinum-resistant, ARID1a-mutated ovarian cancer is ongoing, with an update expected this fall. An Investigator-sponsored trial in cholangiocarcinoma is also recruiting patients. For NXP900, three cohorts have been completed in the dose escalation trial without dose-limiting toxicities.

Financial highlights include:

• Cash and equivalents of $18.1 million as of June 30, 2024
• Net loss of $4.4 million for Q2 2024, down from $5.8 million in Q2 2023
• R&D expenses decreased to $2.9 million from $4.3 million year-over-year
• G&A expenses increased slightly to $1.7 million